Anti-Helicobacter pylori medications in Japan usually refer to triple therapy (proton pump inhibitor + amoxicillin + clarithromycin), where some pharmaceutical companies make a combination of the three types of medications and standardize treatment through a 7-day course of oral administration. Triple therapy refers to the eradication of H. pylori by proton pump inhibitors (PPIs) or potassium-competitive acid blockers (P-CAB) in combination with two antibiotics (amoxicillin, clarithromycin, or metronidazole, among others). Proton pump inhibitors (PPIs) or potassium-competitive acid blockers (P-CAB) are generally chosen from one of the drugs such as omeprazole, lansoprazole, rabeprazole, vonorazan, and revalazan. The choice of two antibiotics is usually the standard regimen of amoxicillin + clarithromycin, with metronidazole being considered instead in clarithromycin-resistant individuals. Some people who cannot be eradicated by standard treatment must undergo antimicrobial susceptibility testing to select the drug. There are significant differences between the treatment regimens for H. pylori in China and Japan, and some drugs are not available in China. Currently, most anti-H. pylori treatments in China are quadruple therapy (proton pump inhibitor + bismuth + two antibiotics) or the current latest high-dose proton pump inhibitor + high-dose amoxicillin therapy. The dosage and safety assessment of specific drugs should be carried out under the guidance of specialized physicians, and should not be taken by oneself to avoid adverse events.